The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial ...

An international study led by researchers at the University of Colorado Anschutz Medical Campus has identified a promising strategy to enhance the safety of nanomedicines, advanced therapies often ...

The US Food and Drug Administration held off a legal challenge from a coalition of blue states over the abortion pill, ...

The FDA is expected to decide on treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis.

Boston Scientific announced the FDA approval of expanded labeling for its pulsed field ablation system which now includes ...

BrainStorm Cell Therapeutics issued a statement Tuesday supporting a Citizens’ Petition submitted to the FDA requesting the ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Under the new leadership of Marty Makary, the FDA should focus more attention on the critical role of real-world clinical data — such as from health insurance databases — in the ongoing assessment of ...

The U.S. Phase 2 trial aims to evaluate efficacy and safety of CX11 in doses up to 200 mg and different titration schemesThe trial is expected to enroll 250 patients to receive treatment over 36 ...

In his letter, Jones rebuked Kennedy's attacks on his staff as unfounded. "The foods program staff at FDA is the envy of the world in its technical, professional and ethical standards," Jones said.

WASHINGTON — The Food and Drug Administration has authorized a not-for-profit company in California to proceed with clinical trials to study the effectiveness of smoking cannabis to treat post ...

The Food and Drug Administration (FDA) issued a “Study May Proceed” letter, allowing a phase 3 trial to evaluate first-line treatment with amezalpat (TPST-1120) in combination with the current ...